Skip Nav Destination
![]()
You do not currently have access to this content.
Telisotuzumab Vedotin Is Active in MET-Overexpressing Non-Squamous NSCLC Available to Purchase
June 18, 2024
Major Finding: In the phase 2 LUMINOSITY trial of telisotuzumab vedotin monotherapy in previously treated advanced EGFR-wildtype non-squamous NSCLC, the overall response rate was 28.6%.
Concept: A trend toward a higher overall response rate was observed in patients whose tumors had high MET expression.
Impact: Telisotuzumab vedotin may benefit a patient population for whom no MET-targeted therapies are currently available.
RSS Feeds